What does it feel like to take GLP-1s? New survey documents patients’ experiences

It has now been several years since GLP-1 medications were widely introduced for weight loss, transforming both clinical care and public awareness. But as adoption has surged, a new set of questions has emerged: What does it feel like to take these medications? What challenges do patients face beyond weight loss itself? And as demand continues to grow, what factors will determine whether patients can start — and adhere to — treatment long term?

Based on a GoodRx Research survey of more than 580 people who have taken GLP-1 medications, the data show that for many people, the central question is no longer whether GLP-1s work. Instead, life on a GLP-1 is shaped by a more fragile set of factors: how much patients pay, how easily they can refill a prescription, how well their bodies tolerate the drug, and whether those conditions hold long enough for treatment to continue.

In this article, GoodRx, a platform for medication savings, takes a look at the current state of GLP-1 patient experience.

Key takeaways:

• Satisfaction among people using GLP-1s for weight loss is high overall, but it drops sharply among those paying over $1,000 per month.
• Over 1 in 3 people taking GLP-1s face barriers to access, including difficulty filling prescriptions — most often due to shortages. These barriers can disrupt weight-loss treatment and lead to medication switching.
• Nausea is the most commonly reported side effect of GLP-1s used for weight loss. People experiencing side effects also report switching their medication at higher rates (31% versus 19%).
• Most GLP-1 care still happens in person. About 8 in 10 people receive their prescription in person from a primary care provider or specialist, compared with 10% who use telehealth.
• Gender gaps show up in both outcomes and access. Men report higher rates of improved health than women (59% versus 49%), while women are more likely to use online clinics and telehealth to access weight-loss medications.

Satisfaction for GLPs is high until cost intervenes

According to the GoodRx survey, nearly 1 in 8 adults in the U.S. are actively taking a prescription weight-loss medication, and another 8% had tried one in the past.

Overall satisfaction is strong. More than 7 in 10 people who have taken a prescription weight-loss medication report being satisfied, including 40% who say they are very satisfied. But that headline masks a steep cost gradient.

Among people whose medication is fully covered, satisfaction is consistently high: Nearly 43% are very satisfied, and fewer than 14% report dissatisfaction. Satisfaction remains relatively stable for those paying up to $500 per month, suggesting that, for many people, moderate out-of-pocket costs are tolerable when the medication is working.

That pattern breaks down at the highest price points. Among people paying over $1,000 per month, dissatisfaction spikes: Nearly 40% report being very dissatisfied, and fewer than 1 in 3 say they are very satisfied. Cost, more than side effects or age, emerges as one of the clearest predictors of whether someone feels positive about their treatment.

This divide reflects broader coverage realities. GoodRx research shows that tens of millions of commercially insured people in the U.S. lack coverage for GLP-1 drugs approved for weight loss. Even when coverage exists, it is often paired with restrictions like prior authorization or step therapy. The result is a system where satisfaction increasingly depends less on clinical response and more on insurance design.

Age shapes expectations and experiences

Satisfaction also varies sharply by age. Younger adults report far more ambivalence. Among adults ages 18 to 24, fewer than 14% say they are very satisfied. Nearly one-third report neutral feelings and another third report dissatisfaction.

By contrast, adults ages 35 to 64 report the highest satisfaction, with roughly 40% saying they are very satisfied and reporting relatively low dissatisfaction rates. These differences may reflect expectations as much as outcomes: Younger adults appear more sensitive to side effects, cost, or the friction of staying on treatment, while older adults may weigh benefits differently.

Side effects drive switching medications, but not always stopping

Side effects are common, but they don’t affect everyone equally. Nausea is the most commonly reported side effect, followed by constipation, stomach pain, diarrhea, fatigue, and vomiting.

These effects don’t always end treatment, but they often lead to changes. People who experience side effects while taking a GLP-1 are significantly more likely to switch medications than those who don’t. In fact, about 31% of those experiencing side effects switch medications, compared with 19% of those who do not. For many, the GLP-1 journey involves experimentation: adjusting doses, changing drugs, or moving between branded and compounded options in search of something tolerable.

Access problems compound dissatisfaction

Cost is not the only source of instability. More than 1 in 3 people report difficulty filling their prescription, most commonly because the medication was out of stock. Insurance hurdles, pharmacy delays, and repeated trips to different pharmacies remain common.

These access issues matter. People who report difficulty filling their prescription are three times as likely to switch medications as those who do not. And concern about continued access rises steadily with cost: Among people paying $500 to $1,000 per month, more than 1 in 3 say they are very concerned about losing access, compared with 15% of those whose medication is fully covered.

Where care begins, and how it differs

Despite the rise of telehealth, most people who use GLP-1s still enter treatment through traditional medical channels. A majority receive prescriptions via in-person visits with primary care doctors, followed by specialists such as endocrinologists or obesity-medicine healthcare professionals.

But pathways vary by race and gender. White patients are more likely to use online weight-loss clinics, while Black and Hispanic patients more often rely on in-person care, particularly primary care physicians. Women are also more likely than men to use online clinics, while men are more likely to receive prescriptions directly through their regular doctor.

These differences matter because access challenges, such as refill difficulty and medication switching, show up across every care pathway, suggesting that no single model has solved the problem of continuity.

GLPs can improve overall health, but not for everyone

Just over half of people report that their overall health has improved since starting a weight-loss medication. Men are more likely than women to report health improvements (59% versus 49%), while women are more likely to report no change or worsening health.

A fragile success

GLP-1 medications have reshaped what’s possible in weight care. For many, GLP-1s deliver real benefits and sustained satisfaction. But the data suggest that this success is conditional. For a small but meaningful share of people, the experience falls short, not because the medication fails outright, but because the surrounding system does.

High costs erode satisfaction. Side effects drive medication switching. Supply disruptions interrupt care. Insurance rules determine who can stay on treatment and who cannot. For many people taking a GLP-1 is less about the promise of the drug itself and more about whether the health care system can support them long enough for that promise to hold.

Methodology

The GoodRx survey was run through YouGov from August through October 2025. The sample population was adults who reported having taken a GLP-1 medication for weight loss. Of the 1,000 adults surveyed, 585 responses were screened in for current or previous GLP-1 medication use for weight loss. Survey responses were weighted to the U.S. population using age, gender, race, political affiliation, and education level. The YouGov survey research arm provides additional details on methodology and weighting.

This story was produced by GoodRx and reviewed and distributed by Stacker.